Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.

Journal: Cell

Published: 2020-10-28

DOI: 10.1016/j.cell.2020.10.037

Affiliations: 20

Authors: 55

Go to article
Institutions Share
Institute for Systems Biology (ISB), United States of America (USA) 0.64
Providence St. Joseph Health, United States of America (USA) 0.05
Swedish Medical Center, United States of America (USA) 0.04
University of Washington (UW), United States of America (USA) 0.04
UCSF Diabetes Center, United States of America (USA) 0.04
Center for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute, United States of America (USA) 0.04
IsoPlexis Corporation, United States of America (USA) 0.04
Stanford Institute for Immunity, Transplantation and Infection (ITI), United States of America (USA) 0.02
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.02
Fred Hutchinson Cancer Research Center (FHCRC), United States of America (USA) 0.02
Vaccine and Infectious Disease Division (VIDD), FHCRC, United States of America (USA) 0.02
Clinical Research Division, FHCRC, United States of America (USA) 0.01
Cape Town HVTN Immunology Laboratory (CHIL) / Hutchinson Centre Research Institute of South Africa, South Africa 0.01
Public Health Sciences Division (PHS), FHCRC, United States of America (USA) 0.01
Stanford Department of Microbiology and Immunology, United States of America (USA) 0.01
Division of Allergy and Infectious Diseases, UW, United States of America (USA) 0.01
Stanford University, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER